CPC C07K 16/22 (2013.01) [A61K 39/3955 (2013.01); A61P 3/00 (2018.01); A61P 3/04 (2018.01); A61P 21/00 (2018.01); A61P 21/04 (2018.01); A61P 21/06 (2018.01); A61K 2039/505 (2013.01); A61K 45/06 (2013.01); C07K 14/475 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/71 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] | 8 Claims |
1. A method for improving body composition in a subject in need thereof, the method comprising administering to the subject a pro/latent myostatin inhibitor in an amount effective to alter body composition, wherein the pro/latent myostatin inhibitor is an antibody or antigen-binding fragment thereof comprising:
(a) a heavy chain amino acid sequence that is at least 95% identical to SEQ ID NO: 50 and a light chain amino acid sequence that is at least 95% identical to SEQ ID NO: 51;
(b) a heavy chain variable region sequence that is at least 95% identical to SEQ ID NO: 73 and a light chain variable region sequence that is at least 95% identical to SEQ ID NO: 74; or
(c) a heavy chain variable region sequence that is at least 95% identical to SEQ ID NO: 78 and a light chain variable region sequence that is at least 95% identical to SEQ ID NO: 79.
|